Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
Iktosiktos.ai · Low evidenceIktos integrates generative AI and robotics to automate the drug discovery process. Its platform combines AI-driven molecular design, retrosynthesis planning, and automated synthesis and testing to rapidly identify drug candidates.
Parse Score
Sources
mauriziochirivainternati.com shapes more of what AI says about Iktos than any other source, at 40% of its citations.
biotechgate.com · deltawave.fr · fastdatascience.com · iambic.ai
Excerpts where Iktos appeared in the AI's answer
Iktos Makya (which utilizes generative deep learning tied to synthetic accessibility constraints)
Iktos (Makya & Spaya) : Best-in-class for synthesis-aware generative design.
Excerpts where Iktos appeared in the AI's answer
Iktos: Applies generative models to automate de novo design and retrosynthesis
Iktos: Provides generative models for de novo design, allowing researchers to create molecules that meet specific ADMET and selectivity profiles.
Excerpts where Iktos appeared in the AI's answer
Iktos : Uses generative software (Makya ) for de novo ligand design and retrosynthesis prediction (Spaya )
